Samantha Du's Quan Capital, Lilly Asia back China's first big kidney play
It’s been a good couple years for kidney biotechs. Once a barren field, it has since been filled with new companies from blue-chip VC firms such as Arch, Versant and Third Rock. Now some top-flight Chinese investors are getting in on the action.
Shanghai-based Alebund Pharmaceuticals announced Monday that they raised a $60 million Series B led by Quan Capital, the VC firm from Zai Lab co-founder and CEO Samantha Du. Quan joined Lilly Asia Ventures, which incubated the company beginning in 2018, among the new company’s most prominent backers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.